최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기대한유전성대사질환학회지 = Journal of the Korean Society of Inherited Metabolic Disease, v.14 no.1, 2014년, pp.42 - 47
김유미 (소아청소년과, 양산 부산대 어린이병원)
Gaucher disease is a multisystemic disorder arising from a deficient activity of the lysosomal enzyme glucocerebrosidase, which leads to accumulation of glycosylceraide and other glycolipids in the regiculoendothelial system. The characteristics of Gaucher disease are anemia, thrombocytopenia, hepat...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
고셔병 1형의 경우에는 어떤 합병증이 나타날 수 있는가? | 고셔병은 무증상에서부터 신생아 사망에 이르기까지 다양한 임상 증상을 보이며, 증상 발생 시기와 신경 증상 여부에 따라 1형, 2형, 3형으로 분류되었다. 1형의 경우 신경계 비침투형으로 현재 분류되고 있으나 실제 말초신경병증, 파킨슨병 등의 신경 합병증이 보고 된다2, 3) . 신경계 비침투형 환자들의 대부분은 소아기에 증상이 발현되어 20세 이전에 진단되는데 주로 골 통증, 대퇴골 단두의 무혈성 괴사, 병적인 골절 등의 골격계 질환, 간비종대, 빈혈, 혈소판감소의 증상을 보이며 발병 시기가 빨랐던 환자 일수록 질환의 진행이 심하고 추후 합병증 발생의 위험도가 높겠다4, 5) . | |
고셔병이란 무엇인가? | 고셔병(OMIM 230800, 230900, 231000)은 상염색체 열성 유전질환으로 염색체 1q21에 존재하는 GBA 유전자의 변이로 발생된 라이소좀내 글루코세레브로시 다제(glucocerebrosidase) 효소의 결핍으로 인해 망상내피세포계에 글루코실세라마이드(glucosyl ceramid) 와 여러 글리코지질 물질들이 축적됨에 따라 발병된다1) . 현재 300 여개 이상의 GBA 유전자의 변이가 알려져 있으며 국내 70여명의 환자 중에서 50여명이 효소 대체 요법을 받고 있다. | |
고셔병은 어떤 요인에 따라 1,2,3형으로 분류되는가? | 현재 300 여개 이상의 GBA 유전자의 변이가 알려져 있으며 국내 70여명의 환자 중에서 50여명이 효소 대체 요법을 받고 있다. 고셔병은 무증상에서부터 신생아 사망에 이르기까지 다양한 임상 증상을 보이며, 증상 발생 시기와 신경 증상 여부에 따라 1형, 2형, 3형으로 분류되었다. 1형의 경우 신경계 비침투형으로 현재 분류되고 있으나 실제 말초신경병증, 파킨슨병 등의 신경 합병증이 보고 된다2, 3) . |
Brady RO, Kanfer J, Shapiro D. The Metabolism of Glucocerebrosides. I. Purification and Properties of a Glucocerebroside-Cleaving Enzyme from Spleen Tissue. J Biol Chem 1965;240:39-43.
Biegstraaten M, Mengel E, Marodi L, Petakov M, Niederau C, Giraldo P, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 2010;133:2909-19.
Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001;73:313-21.
Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004;144:112-20
Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-8.
Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-9.
Elstein D, Zimran A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics 2009;3:407-17.
Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 2008;73:430-40.
Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis:a structured review of the literature. Pharmacoeconomics 2007;25:913-33.
Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, et al. Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014 Mar 18.[Epub ahead of print]
Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Hughes DA, Waldek S, Logan S. Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014 Feb 11.[Epub ahead of print]
Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis 2008;40:428-32.
Halperin A, Elstein D, Zimran A. Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease? Acta Neurol Scand 2007;115:275-8.
Orenstein M, Barbouth D, Bodamer OA, Weinreb NJ. Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes. Orphanet J Rare Dis 2014;9:45.
Sidransky E, Ginns EI, Westman JA, Ehmann WC. Pathologic fractures may develop in Gaucher patients receiving enzyme replacement therapy. Am J Hematol 1994;47:247-9.
Ida H, Rennert OM, Kato S, et al. Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inherit Metab Dis 1999;22:63-73.
Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 2009;84:208-14.
Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, et al. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype. Am J Hematol 2010;85:340-5.
Biegstraaten M, Mengel E, Marodi L, Petakov M, Niederau C, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 2010;133:2909-19.
Lo SM, Liu J, Chen F, Pastores GM, Knowles J, Boxer M, et al. Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy. J Inherit Metab Dis 2011;34:643-50.
Lachmann RH, Wight DG, Lomas DJ, Fisher NC, Schofield JP, Elias E, et al. Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM 2000;93:237-44.
Bohte AE, van Dussen L, Akkerman EM, Nederveen AJ, Sinkus R, Jansen PL, et al. Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One 2013;8:e57507.
Thomas AS, Mehta A, Hughes DA. Gaucher disease:haematological presentations and Complications. Br J Haematol 2014;165:427-40.
Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, et al. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis 2010;33:291-300.
Peric Z1, Kardum-Skelin I, Puskaric BJ, Letilovic T, Vrhovac R, Jaksic B. An unusual presentation of Gaucher's disease: aortic valve fibrosis in a patient homozygous for a rare G377S mutation. Coll Antropol 2010;34:275-8.
Henderson JM, Gilinsky NH, Lee EY, Greenwood MF. Gaucher's disease complicated by bleeding esophageal varices and colonic infiltration by Gaucher cells. Am J Gastroenterol 1991;86:346-8.
Jones DR, Hoffman J, Downie R, Haqqani M. Massive gastrointestinal hemorrhage associated with ileal lymphoid hyperplasia in Gauchers-disease. Postgrad 1991;67:479-81.
Lee BH, Kim DY, Kim GH, Cho KJ, Yoon HK, Yoo HW. Progressive mesenteric lymphadenopathy with protein-losing enteropathy; a devastating complication in Gaucher disease. Mol Genet Metab 2012;105:522-4.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.